Signe BioPharma Inc is dedicated to the eradication of breast cancer. To achieve this goal, new treatments are planned based on the concept of personalized medicine.
New immunodiagnostic and molecular diagnostic tests will identify the type of targeted therapy needed for each individual, including those with advanced stage or "triple negative" breast cancer. Signe will offer new unique targeted therapies. However, Signe recognizes that the surest means of eradication is prevention. Risk reduction programs will be developed based on the body's natural secretory immune system. Extensions of this information will lead to full preventions based on oral immunizations that can be used world wide.
Beyond breast cancer, Signe BioPharma plans application of its personalized medicine technology to the treatment of other common cancers arising from prostate, colon, ovary, uterus, cervix, bladder, kidney, pancreas and lung. Indeed, Signe's therapies will be designed to treat most cancers, including advanced stage cancers.
To accomplish these goals, large supplies of therapeutic proteins will be needed. Signe BioPharma Inc will produce these proteins using highly adaptable transgenic plant-based platforms that permit rapid testing of new therapeutics and that facilitate low cost large scale production of therapeutic and prevention proteins for world markets.